Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785507 | 1.00 | FOLH1 (0.48) | FOLH1CPA3CYP1A2KIF11CYP2C19 | |
| SCHEMBL11267940 | 0.88 | CHRM2 (0.43) | FOLH1CPA3CYP1A2CYP2C19TSHR | |
| SCHEMBL11245351 | 0.85 | FOLH1 (0.42) | FOLH1CPA3CYP1A2KIF11CYP2C19 | |
| SCHEMBL1160457 | 0.80 | FOLH1 (0.49) | FOLH1CPA3KIF11 | |
| SCHEMBL17913818 | 0.80 | FOLH1 (0.49) | FOLH1CPA3KIF11 | |
| SCHEMBL7828921 | 0.79 | ANPEP (0.52) | FOLH1CPA3KIF11 | |
| SCHEMBL27346918 | 0.76 | TSHR (0.47) | CYP1A2KIF11CYP2C19TSHR | |
| SCHEMBL4797477 | 0.76 | KIF11 (0.53) | KIF11 | |
| SCHEMBL27349964 | 0.76 | TSHR (0.47) | CYP1A2KIF11CYP2C19TSHR | |
| SCHEMBL3185210 | 0.73 | CYP2C19 (0.40) | CYP1A2KIF11CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | claimed |
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | ASCENDIS PHARMA A/S (DK) | 2025-04-24 | — | — | US | disclosed |
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | disclosed |
| US-11965851-B2 | Grid coatings for capture of proteins and other compounds | PURDUE RESEARCH FOUNDATION (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024069229-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2024-04-04 | — | — | WO | disclosed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2022-10-20 | — | — | US | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220288229-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-09-15 | — | — | US | disclosed |
| US-20050256301-A1 | Cyclised conotoxin peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-11-17 | — | — | US | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0013261-B1 | GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1982-12-01 | — | — | EP | disclosed |
| US-4350628-A | OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE | RESEARCH CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4299842-A | TREATMENT OF RESPIRATORY SYSTEM DISORDERS, NUCOLYTIC AGENTS | CAVAZZA CLAUDIO | 1981-11-10 | — | — | US | disclosed |
| US-4283328-A | TREATING AN N-BLOCKED AMINO ACID RESIDUE WITH A TETRAMETHYL GUANIDINIUM SALT OF A PEPTIDE CHAIN | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4261884-A | DESIRABLE BIOLOGICAL PROPERTIES AND STABILITY TO ENZYME CLEAVAGE | RESEARCH CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0013261-A1 | Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1980-07-09 | — | — | EP | disclosed |
| EP-0010830-A2 | Dehydropeptides | Research Corporation (US) | 1980-05-14 | — | — | EP | disclosed |
| US-4113714-A | GROWTH HORMONE RELEASE INHIBITING UNDECAPEPTIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288229-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | CD47, CD44, FURIN | FOLH1 11/4885CPA3 100/4885CYP1A2 3115/4885 |
| US-20050256301-A1 | Cyclised conotoxin peptides | VIP, CANX, IAPP | FOLH1 1079/4885CPA3 29/4885CYP1A2 2114/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | FOLH1 17/4885CPA3 575/4885CYP1A2 4882/4885 |
| US-11965851-B2 | Grid coatings for capture of proteins and other compounds | CD2BP2, CDC37, CD68 | FOLH1 1417/4885CPA3 2650/4885CYP1A2 4501/4885 |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | FOLH1 651/4885CPA3 627/4885CYP1A2 262/4885 |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | H1-0, H1-3, DLST | FOLH1 620/4885CPA3 693/4885CYP1A2 263/4885 |
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | H1-0, H1-3, DLST | FOLH1 620/4885CPA3 693/4885CYP1A2 263/4885 |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | FOLH1 54/4885CPA3 48/4885CYP1A2 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.